Results 241 to 250 of about 222,217 (297)
Cyclophosphamide pharmacokinetics in children
British Journal of Clinical Pharmacology, 1996 1. Cyclophosphamide pharmacokinetics were measured in 38 children with cancer. 2. A high degree of inter-patient variation was seen in all pharmacokinetic parameters. Cyclophosphamide half-life varied between 1.1. and 16.8 h, clearance varied between 1.2
Jeff Idle, Alan V. Boddy, A D Pearson
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cancer Chemotherapy and Pharmacology, 1981
Little information is available about the effect of cytotoxic drugs on diabetes mellitus. Cyclophosphamide has been reported to be a possible cause of mild diabetes [2], but Kruger [1] described two diabetics whose blood sugar levels fell during treatment with cyclophosphamide.
R G, Henderson, R D, Rubens
openaire +2 more sources
Little information is available about the effect of cytotoxic drugs on diabetes mellitus. Cyclophosphamide has been reported to be a possible cause of mild diabetes [2], but Kruger [1] described two diabetics whose blood sugar levels fell during treatment with cyclophosphamide.
R G, Henderson, R D, Rubens
openaire +2 more sources
Journal of Pharmaceutical Sciences, 1972
A GLC procedure was developed for the assay of cyclophosphamide raw materials and cyclophosphamide in formulations. Results obtained by this technique are comparable to those obtained by IR spectroscopy. The GLC procedure offers increased accuracy, reproducibility, and precision. The method is more specific and less time consuming than the IR procedure.
O D, Boughton +4 more
openaire +2 more sources
A GLC procedure was developed for the assay of cyclophosphamide raw materials and cyclophosphamide in formulations. Results obtained by this technique are comparable to those obtained by IR spectroscopy. The GLC procedure offers increased accuracy, reproducibility, and precision. The method is more specific and less time consuming than the IR procedure.
O D, Boughton +4 more
openaire +2 more sources
Cyclophosphamide cardiotoxicity
European Journal of Pediatrics, 1980A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide (4 x 50 mg/kg on four consecutive days) given as preparation for bone marrow grafting. This and previously reported cases demonstrate the possibility of cardiotoxicity after high doses of the drug.
G, von Bernuth +6 more
openaire +2 more sources
Cyclophosphamide in dermatology
Australasian Journal of Dermatology, 2016AbstractCyclophosphamide is a chemotherapeutic agent which was first discovered in experimental tumours in rats, and it has since been widely used to treat malignancies and severe manifestations of various auto‐immune diseases. High‐dose chemotherapy and continuous daily oral regimens are associated with significant toxicity profiles, but i.v.
Janet, Kim, Jonathan J, Chan
openaire +2 more sources
Cyclophosphamide in Pregnancy*
Australian and New Zealand Journal of Obstetrics and Gynaecology, 1970Summary: Cyclophosphamide was given to a young woman with nephrotic syndrome, and was inadvertently continued until the eighth week of her pregnancy. The baby had only two minor malformations; an umbilical hernia and a cutaneous haemangioma, which were probably not due to the cyclophosphamide.
openaire +2 more sources
Novel class of cyclophosphamide prodrug: Cyclophosphamide spiropiperaziniums (CPSP)
Bioorganic & Medicinal Chemistry Letters, 2006AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Qi, Sun +5 more
openaire +2 more sources
Clinical Pharmacokinetics of Cyclophosphamide
Clinical Pharmacokinetics, 2005Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug.
de Jonge, M.E. +3 more
openaire +3 more sources